Vinay Prasad was reinstated as director of the FDA's Center for Biologics Evaluation and Research (CBER) just two weeks after his removal, following a campaign that criticized his previous stances and alleged political intervention. His return was encouraged by FDA Commissioner Marty Makary, signaling potential shifts in the agency's leadership and regulatory approach. Industry and Wall Street responses were mixed, impacting stocks of companies with ties to CBER.